TROP2 Antibody-Drug Conjugate Composition for Solid Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates for treating solid tumors face challenges in effectively targeting and delivering cytotoxic agents to TROP2-expressing cancer cells due to suboptimal construction of antibodies, cytotoxins, and linkers, leading to inadequate clinical outcomes.
Innovation Solution
A novel antibody-drug conjugate structure (Formula I) is developed, comprising an antibody that binds to TROP2, a specific cytotoxin, and a linker, optimized for targeted delivery to solid tumors, with administration schedules and dosages tailored for effective treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody-drug conjugates are used for treating solid tumors, then the treatment can be administered with existing protocols, but the therapeutic efficacy is insufficient due to suboptimal construction of antibodies, cytotoxins, and linkers
Solution Approach 1:
The patent optimizes key parameters of the ADC including the drug-to-antibody ratio (DAR), linker length and composition, and cytotoxin selection to achieve enhanced therapeutic efficacy. Specifically, the patent employs linkers with controlled hydrophobicity and length, selects cytotoxins with appropriate potency and specificity, and adjusts the DAR to maximize tumor cell killing while minimizing off-target effects, thereby resolving the contradiction between efficacy and construction complexity
Solution Approach 2:
The patent creates an optimized composite structure by combining specifically selected antibody components, cytotoxin molecules, and linker sequences into a unified ADC construct. This composite approach allows the synergistic integration of each component's strengths - the antibody's targeting capability, the cytotoxin's killing potency, and the linker's stability and release kinetics - to achieve superior therapeutic efficacy that overcomes the limitations of conventional ADCs
2Measurement precision
If the antibody-drug conjugate is designed with high specificity for TROP2, then targeted delivery to tumor cells is improved, but the complexity of optimizing the three components increases
Solution Approach 1:
The patent applies local quality optimization by focusing the ADC's targeting specificity on the TROP2 antigen-expressing tumor cells while minimizing interactions with non-target tissues. This is achieved through careful selection and optimization of the antibody component's binding affinity and specificity for TROP2, ensuring that the conjugate delivers cytotoxin preferentially to TROP2-positive cells, thereby achieving high targeting precision without requiring complex multi-component optimization
Solution Approach 2:
The patent employs the linker as an intermediary component that facilitates the controlled release of cytotoxin from the antibody conjugate. The linker is designed with specific properties including appropriate hydrophobicity, length, and cleavability to ensure stable circulation of the intact ADC while enabling efficient cytotoxin release upon internalization by TROP2-positive tumor cells, thereby simplifying the optimization process by decoupling the targeting and cytotoxic functions
3Productivity
If the cytotoxin molecule is made sufficiently active with broad spectrum, then tumor cell killing is enhanced, but the side effects and toxicity to normal cells increase
Solution Approach 1:
The patent extracts the cytotoxic function from the targeting function by using a separate cytotoxin molecule that is only activated upon delivery to tumor cells. The highly potent cytotoxin is kept inactive during circulation as part of the stable ADC conjugate, and is only released and activated after internalization by TROP2-positive tumor cells, thereby enabling the use of broadly active cytotoxins without exposing normal cells to their toxic effects
Solution Approach 2:
The patent converts the potentially harmful broad-spectrum cytotoxic activity into a beneficial targeted therapy by coupling it with TROP2-specific antibody targeting. The cytotoxin's inherent toxicity, which would be harmful if released systemically, is transformed into a therapeutic benefit by ensuring its release is spatially and temporally restricted to the tumor cell interior, where it exerts its killing effect selectively on cancer cells while sparing normal tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized antibody-drug conjugate achieves enhanced therapeutic efficacy by specifically targeting TROP2-positive solid tumors, improving clinical outcomes through targeted cytotoxin delivery and reduced side effects.
Implementation Method 1
Abu is an antibody or an antigen-binding unit thereof that binds to TROP2
Implementation Method 2
D is drug... the cytotoxin molecule should be sufficiently active and have a broad spectrum for the tumor cells
Data Source
AI summary
The disclosed relates to the field of pharmaceutical therapeutic methods. Disclosed is a method for treating a solid tumor. The methods disclosed include treating solid tumors with antibody drug conjugate. The disclosed method includes administering to a patient with a solid tumor an effective amount of a TROP2-targeted antibody-drug conjugate.